Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Oct 29, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed October 29, 2025
Period End
October 29, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported on October 29, 2025 positive topline results from CALIBRATE, its global Phase 3 study of encaleret, an investigational oral negative allosteric modulator of the calcium-sensing receptor, in patients with autosomal dominant hypocalcemia type 1 (ADH1).

The study enrolled 70 adults and randomized 67 participants in a 2:1 ratio (encaleret vs. standard of care). The primary endpoint, achievement of both target serum and urine calcium ranges at Week 24, was met by 76%a of encaleret-treated participants (34 of 45) versus 4% (2 of 45) on conventional therapy (p<0.0001). Key secondary endpoints were also met: 91% of participants on encaleret achieved intact PTH above the lower limit of the reference range at Week 24 versus 7% on conventional therapy at Week 4 (p<0.0001).

The filing states that encaleret was well-tolerated, with no discontinuations related to study drug, and that safety findings were generally consistent with known ADH1 biology or related to the drug's mechanism of action. Among additional results, encaleret produced a mean increase in corrected calcium of 0.82 mg/dL from Week 4 to Week 24 (p<0.0001) and a mean reduction of 200 mg/day in 24-hour urine calcium over the same period (p<0.0001). 65 of 67 randomized participants (97%b) elected to continue in the ongoing long-term extension.

Management plans to submit a New Drug Application to the FDA in the first half of 2026 to support full approval, followed by a Marketing Authorization Application to the EMA. BridgeBio also plans to start a registrational trial in pediatric ADH1 in Q1 2026 and a Phase 3 study in adults with chronic hypoparathyroidism in 2026.

Encaleret holds FDA Fast Track Designation and Orphan Drug Designation in the U.S., EU, and Japan. The company hosted an investor call on October 29, 2025 at 8:00 am ET to discuss the results.

Key Highlights

  1. Phase 3 CALIBRATE study of encaleret met its primary endpoint: 76% of treated participants (34 of 45) achieved both target serum and urine calcium at Week 24 vs. 4% (2 of 45) on conventional therapy (p<0.0001).
  2. Key secondary endpoint met: 91% of encaleret participants achieved intact PTH above the lower limit of the reference range at Week 24 vs. 7% on conventional therapy at Week 4 (p<0.0001).
  3. At Week 20, 98% (44 of 45) of encaleret participants had albumin-corrected serum calcium in the target range, vs. 33% (7 of 21) on conventional therapy.
  4. Encaleret was well-tolerated, with no discontinuations related to study drug.
  5. Regulatory plans: NDA submission to the FDA planned for the first half of 2026 to support full approval, with an EMA Marketing Authorization Application to follow.
  6. Additional indications planned: pediatric ADH1 registrational trial to start in Q1 2026 and a Phase 3 study in adults with chronic hypoparathyroidism in 2026.
  7. 65 of 67 randomized participants (97%) elected to continue in the ongoing long-term extension study.

Frequently Asked Questions

  1. What did the CALIBRATE Phase 3 study of encaleret show?

    The study met all pre-specified primary and key secondary efficacy endpoints in adults with ADH1. The primary endpoint, achieving both target serum and urine calcium at Week 24, was reached by 76% of encaleret participants versus 4% on conventional therapy (p<0.0001).

  2. What is encaleret and what indication is it being developed for?

    Encaleret is an investigational, orally administered small molecule that selectively negatively modulates the calcium-sensing receptor. It is being developed to treat autosomal dominant hypocalcemia type 1 (ADH1) and has received FDA Fast Track Designation and Orphan Drug Designation in the U.S., EU, and Japan.

  3. How was the safety profile of encaleret described?

    The company stated that encaleret was well-tolerated, with no discontinuations related to study drug. It said safety findings were generally consistent with known ADH1 biology or related to the drug's mechanism of action.

  4. What are the next regulatory and development steps?

    BridgeBio plans to submit a New Drug Application to the FDA in the first half of 2026 to support full approval, followed by a Marketing Authorization Application to the EMA. It also plans to start a pediatric ADH1 registrational trial in Q1 2026 and a Phase 3 study in adults with chronic hypoparathyroidism in 2026.

  5. What did the company say about the study's effect on calcium levels?

    Encaleret produced a mean increase in corrected calcium of 0.82 mg/dL from Week 4 to Week 24 (p<0.0001) and a mean reduction of 200 mg/day in 24-hour urine calcium over the same period (p<0.0001). By Day 3 after randomization, 71% (32 of 45) of encaleret participants had albumin-corrected serum calcium within the reference range.